Trade Jazz Pharmaceuticals plc - JAZZ CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
- Ownership
| Spread | 0.23 | ||||||||
|
Long position overnight fee
Long position overnight fee
Go to platform | -0.026151% | ||||||||
|
Short position overnight fee
Short position overnight fee
Go to platform | 0.003929% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
*Information provided by Capital.com
Jazz Pharmaceuticals PLC ESG Risk Ratings
‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.
| Prev. Close* | 132.55 |
| Open* | 132.95 |
| 1-Year Change* | -0.26% |
| Day's Range* | 131.17 - 133.44 |
| 52 wk Range | 120.64-160.96 |
| Average Volume (10 days) | 518.32K |
| Average Volume (3 months) | 11.14M |
| Market Cap | 8.57B |
| P/E Ratio | -100.00K |
| Shares Outstanding | 63.13M |
| Revenue | 3.76B |
| EPS | -1.77 |
| Dividend (Yield %) | N/A |
| Beta | 0.71 |
| Next Earnings Date | Nov 6, 2023 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Sep 22, 2023 | 131.66 | -0.21 | -0.16% | 131.87 | 133.45 | 130.81 |
| Sep 21, 2023 | 132.55 | 0.03 | 0.02% | 132.52 | 133.22 | 131.51 |
| Sep 20, 2023 | 133.14 | 2.42 | 1.85% | 130.72 | 133.95 | 130.72 |
| Sep 19, 2023 | 131.27 | 0.21 | 0.16% | 131.06 | 132.68 | 130.68 |
| Sep 18, 2023 | 132.24 | 0.52 | 0.39% | 131.72 | 132.87 | 131.43 |
| Sep 15, 2023 | 131.95 | -1.00 | -0.75% | 132.95 | 133.85 | 131.63 |
| Sep 14, 2023 | 133.65 | 0.10 | 0.07% | 133.55 | 135.25 | 133.08 |
| Sep 13, 2023 | 133.99 | 0.80 | 0.60% | 133.19 | 135.40 | 133.01 |
| Sep 12, 2023 | 135.57 | 0.53 | 0.39% | 135.04 | 136.78 | 134.50 |
| Sep 11, 2023 | 136.31 | -0.17 | -0.12% | 136.48 | 137.44 | 135.09 |
| Sep 8, 2023 | 136.27 | 1.32 | 0.98% | 134.95 | 136.96 | 134.95 |
| Sep 7, 2023 | 135.66 | 0.19 | 0.14% | 135.47 | 136.72 | 135.21 |
| Sep 6, 2023 | 136.45 | -2.07 | -1.49% | 138.52 | 139.02 | 135.91 |
| Sep 5, 2023 | 138.75 | -3.19 | -2.25% | 141.94 | 142.46 | 138.49 |
| Sep 1, 2023 | 143.65 | 0.34 | 0.24% | 143.31 | 144.37 | 142.72 |
| Aug 31, 2023 | 143.21 | -0.33 | -0.23% | 143.54 | 146.35 | 142.72 |
| Aug 30, 2023 | 145.19 | 2.71 | 1.90% | 142.48 | 145.56 | 142.47 |
| Aug 29, 2023 | 143.60 | 2.28 | 1.61% | 141.32 | 143.72 | 140.97 |
| Aug 28, 2023 | 142.00 | 0.95 | 0.67% | 141.05 | 142.41 | 140.84 |
| Aug 25, 2023 | 141.16 | 3.76 | 2.74% | 137.40 | 141.66 | 137.40 |
Jazz Pharmaceuticals plc Events
| Time (UTC) | Country | Event |
|---|---|---|
| Monday, November 6, 2023 | ||
| Time (UTC) 21:05 | Country IE
| Event Q3 2023 Jazz Pharmaceuticals PLC Earnings Release Q3 2023 Jazz Pharmaceuticals PLC Earnings ReleaseForecast -Previous - |
| Monday, February 26, 2024 | ||
| Time (UTC) 21:05 | Country IE
| Event Q4 2023 Jazz Pharmaceuticals PLC Earnings Release Q4 2023 Jazz Pharmaceuticals PLC Earnings ReleaseForecast -Previous - |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Total revenue | 3659.37 | 3094.24 | 2363.57 | 2161.76 | 1890.92 |
| Revenue | 3659.37 | 3094.24 | 2363.57 | 2161.76 | 1890.92 |
| Cost of Revenue, Total | 540.517 | 440.76 | 148.917 | 127.93 | 121.544 |
| Gross Profit | 3118.86 | 2653.48 | 2214.65 | 2033.83 | 1769.38 |
| Total Operating Expense | 3724.9 | 2923.96 | 1990.59 | 1629.39 | 1277.51 |
| Selling/General/Admin. Expenses, Total | 1376.17 | 1222.68 | 854.233 | 736.942 | 683.53 |
| Research & Development | 1034.6 | 505.748 | 586.625 | 409.701 | 226.616 |
| Depreciation / Amortization | 599.169 | 525.769 | 259.58 | 354.814 | 201.498 |
| Unusual Expense (Income) | 174.448 | 229 | 141.239 | 0 | 44.321 |
| Operating Income | -65.528 | 170.278 | 372.973 | 532.374 | 613.413 |
| Interest Income (Expense), Net Non-Operating | -307.256 | -283.116 | -97.878 | -78.072 | -86.153 |
| Net Income Before Taxes | -372.784 | -112.838 | 275.095 | 454.302 | 527.26 |
| Net Income After Taxes | -214.139 | -328.954 | 241.578 | 527.456 | 447.091 |
| Minority Interest | |||||
| Net Income Before Extra. Items | -224.06 | -329.668 | 238.616 | 523.367 | 447.091 |
| Net Income | -224.06 | -329.668 | 238.616 | 523.367 | 447.098 |
| Income Available to Common Excl. Extra. Items | -224.06 | -329.668 | 238.616 | 523.367 | 447.091 |
| Income Available to Common Incl. Extra. Items | -224.06 | -329.668 | 238.616 | 523.367 | 447.098 |
| Dilution Adjustment | 0 | ||||
| Diluted Net Income | -224.06 | -329.668 | 238.616 | 523.367 | 447.098 |
| Diluted Weighted Average Shares | 62.539 | 59.694 | 56.517 | 57.55 | 61.221 |
| Diluted EPS Excluding Extraordinary Items | -3.58272 | -5.52263 | 4.22202 | 9.09413 | 7.30289 |
| Diluted Normalized EPS | -1.7696 | -3.02908 | 6.4166 | 9.09413 | 7.91677 |
| Total Extraordinary Items | 0 | 0.0075 | |||
| Equity In Affiliates | -9.921 | -0.714 | -2.962 | -4.089 |
| Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | |
|---|---|---|---|---|---|
| Total revenue | 957.317 | 892.812 | 972.123 | 940.652 | 932.878 |
| Revenue | 957.317 | 892.812 | 972.123 | 940.652 | 932.878 |
| Cost of Revenue, Total | 97.537 | 128.644 | 167.364 | 133.661 | 124.208 |
| Gross Profit | 859.78 | 764.168 | 804.759 | 806.991 | 808.67 |
| Total Operating Expense | 799.681 | 766.757 | 1235.51 | 915.889 | 847.332 |
| Selling/General/Admin. Expenses, Total | 340.844 | 297.917 | 383.203 | 317.678 | 325.673 |
| Research & Development | 209.238 | 190.41 | 547.555 | 148.87 | 208.195 |
| Depreciation / Amortization | 152.062 | 149.786 | 137.387 | 141.232 | 148.456 |
| Unusual Expense (Income) | 0 | 174.448 | 40.8 | ||
| Operating Income | 157.636 | 126.055 | -263.386 | 24.763 | 85.546 |
| Interest Income (Expense), Net Non-Operating | -75.852 | -70.954 | -76.607 | -84.893 | -64.532 |
| Net Income Before Taxes | 81.784 | 55.101 | -339.993 | -60.13 | 21.014 |
| Net Income After Taxes | 106.107 | 70.425 | -239.951 | -17.103 | 37.126 |
| Equity In Affiliates | -1.669 | -1.005 | -0.773 | -2.545 | -2.461 |
| Net Income Before Extra. Items | 104.438 | 69.42 | -240.724 | -19.648 | 34.665 |
| Net Income | 104.438 | 69.42 | -240.724 | -19.648 | 34.665 |
| Income Available to Common Excl. Extra. Items | 104.438 | 69.42 | -240.724 | -19.648 | 34.665 |
| Income Available to Common Incl. Extra. Items | 104.438 | 69.42 | -240.724 | -19.648 | 34.665 |
| Diluted Net Income | 104.438 | 69.42 | -240.724 | -19.648 | 34.665 |
| Diluted Weighted Average Shares | 73.54 | 73.771 | 63.061 | 62.785 | 63.431 |
| Diluted EPS Excluding Extraordinary Items | 1.42015 | 0.94102 | -3.81732 | -0.31294 | 0.5465 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
| Diluted Normalized EPS | 1.42015 | 0.94102 | -3.81732 | 1.49308 | 0.96459 |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Total Current Assets | 2606.14 | 2611.33 | 2839.57 | 1630.27 | 1234.01 |
| Cash and Short Term Investments | 881.482 | 591.448 | 2132.77 | 1077.34 | 824.622 |
| Cash & Equivalents | 517.464 | ||||
| Short Term Investments | 30 | 80.701 | 1615.65 | 744.172 | 609.016 |
| Total Receivables, Net | 742.628 | 563.36 | 396.49 | 355.987 | 263.838 |
| Accounts Receivable - Trade, Net | 651.493 | 563.36 | 396.49 | 355.987 | 263.838 |
| Total Inventory | 714.061 | 1072.72 | 95.396 | 78.608 | 52.956 |
| Prepaid Expenses | 91.912 | 131.413 | 62.422 | 39.434 | 25.017 |
| Other Current Assets, Total | 176.057 | 252.392 | 152.491 | 78.895 | 67.572 |
| Total Assets | 10835.3 | 12298.6 | 6535.9 | 5538.9 | 5203.49 |
| Property/Plant/Equipment, Total - Net | 301.376 | 343.423 | 257.104 | 270.891 | 200.358 |
| Property/Plant/Equipment, Total - Gross | 409.023 | 428.794 | 324.692 | 326.148 | 249.966 |
| Accumulated Depreciation, Total | -107.647 | -85.371 | -67.588 | -55.257 | -49.608 |
| Goodwill, Net | 1692.66 | 1827.61 | 958.303 | 920.018 | 927.63 |
| Intangibles, Net | 5794.44 | 7152.33 | 2195.05 | 2440.98 | 2731.33 |
| Other Long Term Assets, Total | 440.64 | 363.945 | 285.875 | 276.743 | 110.164 |
| Total Current Liabilities | 933.193 | 809.303 | 653.745 | 364.49 | 345.487 |
| Accounts Payable | 90.758 | 100.298 | 26.945 | 47.545 | 40.602 |
| Accrued Expenses | 802.874 | 647.479 | 349.107 | 266.836 | 263.427 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Current Port. of LT Debt/Capital Leases | 31.381 | 31.406 | 246.322 | 33.387 | 33.387 |
| Other Current Liabilities, Total | 8.18 | 30.12 | 31.371 | 16.722 | 8.071 |
| Total Liabilities | 7749.52 | 8333.45 | 2876.16 | 2427.92 | 2446.07 |
| Total Long Term Debt | 5698.55 | 6025.21 | 1848.52 | 1573.87 | 1563.03 |
| Long Term Debt | 5693.34 | 6018.94 | 1848.52 | 1573.87 | 1563.03 |
| Deferred Income Tax | 944.337 | 1300.54 | 130.397 | 224.095 | 309.097 |
| Other Liabilities, Total | 173.44 | 198.392 | 243.498 | 265.461 | 228.46 |
| Total Equity | 3085.73 | 3965.19 | 3659.75 | 3110.98 | 2757.42 |
| Common Stock | 0.061 | 0.061 | 0.061 | 0.061 | 0.061 |
| Additional Paid-In Capital | 3477.12 | 3534.79 | 2633.67 | 2266.03 | 2113.63 |
| Retained Earnings (Accumulated Deficit) | 734.058 | 830.698 | 1160.37 | 1068.29 | 841.522 |
| Other Equity, Total | -1125.51 | -400.36 | -134.352 | -223.393 | -197.791 |
| Total Liabilities & Shareholders’ Equity | 10835.3 | 12298.6 | 6535.9 | 5538.9 | 5203.49 |
| Total Common Shares Outstanding | 63.214 | 61.633 | 56.171 | 56.14 | 57.504 |
| Cash | 334.018 | 510.747 | 517.117 | 333.172 | 215.606 |
| Capital Lease Obligations | 5.21 | 6.269 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Total Current Assets | 2784.65 | 2606.14 | 2571.5 | 2590.83 | 2500.86 |
| Cash and Short Term Investments | 1167.91 | 881.482 | 899.358 | 771.265 | 490.835 |
| Cash | 424.139 | 334.018 | 296.686 | 380.328 | 410.125 |
| Cash & Equivalents | 563.772 | 517.464 | 542.672 | 290.937 | |
| Short Term Investments | 180 | 30 | 60 | 100 | 80.71 |
| Total Receivables, Net | 681.154 | 651.493 | 601.179 | 594.034 | 572.392 |
| Accounts Receivable - Trade, Net | 623.938 | 651.493 | 601.179 | 594.034 | 572.392 |
| Total Inventory | 674.778 | 714.061 | 728.074 | 861.705 | 985.454 |
| Prepaid Expenses | 72.779 | 91.912 | 92.877 | 108.304 | 117.399 |
| Other Current Assets, Total | 188.028 | 267.192 | 250.016 | 255.525 | 334.776 |
| Total Assets | 11047.1 | 10835.3 | 10384.7 | 11200.1 | 11768.9 |
| Property/Plant/Equipment, Total - Net | 303.09 | 301.376 | 290.067 | 317.888 | 341.044 |
| Property/Plant/Equipment, Total - Gross | 419.23 | 409.023 | 388.038 | 414.57 | 433.74 |
| Accumulated Depreciation, Total | -116.14 | -107.647 | -97.971 | -96.682 | -92.696 |
| Goodwill, Net | 1723.44 | 1692.66 | 1592.64 | 1687.65 | 1782.44 |
| Intangibles, Net | 5764.21 | 5794.44 | 5570.39 | 6237.96 | 6783.06 |
| Other Long Term Assets, Total | 471.732 | 440.64 | 360.067 | 365.805 | 361.516 |
| Total Current Liabilities | 908.902 | 933.193 | 812.954 | 705.442 | 737.409 |
| Accounts Payable | 125.454 | 90.758 | 102.249 | 74.161 | 73.336 |
| Accrued Expenses | 711.779 | 803.255 | 630.648 | 569.174 | 596.292 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Current Port. of LT Debt/Capital Leases | 31 | 31 | 31 | 31 | 31 |
| Other Current Liabilities, Total | 40.669 | 8.18 | 49.057 | 31.107 | 36.781 |
| Total Liabilities | 7712.08 | 7749.52 | 7639.47 | 7999.35 | 8160.43 |
| Total Long Term Debt | 5689.66 | 5693.34 | 5695.81 | 5990 | 5992.87 |
| Long Term Debt | 5689.66 | 5693.34 | 5695.81 | 5990 | 5992.87 |
| Deferred Income Tax | 932.247 | 944.337 | 933.67 | 1096.42 | 1222.08 |
| Other Liabilities, Total | 181.273 | 178.65 | 197.035 | 207.496 | 208.069 |
| Total Equity | 3335.04 | 3085.73 | 2745.19 | 3200.78 | 3608.49 |
| Common Stock | 0.061 | 0.061 | 0.061 | 0.061 | 0.061 |
| Additional Paid-In Capital | 3511.73 | 3477.12 | 3388 | 3312.32 | 3239.33 |
| Retained Earnings (Accumulated Deficit) | 803.478 | 734.058 | 974.782 | 994.43 | 959.819 |
| Other Equity, Total | -980.23 | -1125.51 | -1617.65 | -1106.03 | -590.72 |
| Total Liabilities & Shareholders’ Equity | 11047.1 | 10835.3 | 10384.7 | 11200.1 | 11768.9 |
| Total Common Shares Outstanding | 63.987 | 63.214 | 62.89 | 62.623 | 62.244 |
| Capital Lease Obligations |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -224.06 | -329.668 | 238.616 | 523.367 | 447.098 |
| Cash From Operating Activities | 1271.98 | 778.507 | 899.648 | 776.401 | 798.904 |
| Cash From Operating Activities | 30.302 | 26.714 | 18.673 | 15.342 | 15.233 |
| Amortization | 599.169 | 525.769 | 259.58 | 354.814 | 201.498 |
| Deferred Taxes | -292.251 | 69.198 | -136.937 | -236.61 | -88.815 |
| Non-Cash Items | 875.52 | 311.361 | 605.153 | 269.572 | 200.604 |
| Cash Taxes Paid | 94.681 | 271.217 | 226.823 | 183.61 | 164.217 |
| Cash Interest Paid | 270.671 | 138.271 | 42.47 | 43.002 | 42.706 |
| Changes in Working Capital | 283.297 | 175.133 | -85.437 | -150.084 | 23.286 |
| Cash From Investing Activities | -446.23 | -5212.14 | -1007.67 | -155.3 | -394.487 |
| Capital Expenditures | -498.194 | -45.532 | -379.254 | -182.335 | -131.47 |
| Other Investing Cash Flow Items, Total | 51.964 | -5166.61 | -628.416 | 27.035 | -263.017 |
| Cash From Financing Activities | -529.491 | 3970.52 | 528.073 | -293.745 | -479.13 |
| Financing Cash Flow Items | -45.443 | -35.602 | -16.877 | -16.739 | -23.078 |
| Issuance (Retirement) of Stock, Net | 97.966 | 135.261 | -46.856 | -243.619 | -430.335 |
| Issuance (Retirement) of Debt, Net | -582.014 | 3870.86 | 591.806 | -33.387 | -25.717 |
| Foreign Exchange Effects | -6.222 | -3.207 | 0.374 | 0.366 | -1.7 |
| Net Change in Cash | 290.034 | -466.321 | 420.425 | 327.722 | -76.413 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Net income/Starting Line | 69.42 | -224.06 | 16.664 | 36.312 | 1.647 |
| Cash From Operating Activities | 320.708 | 1271.98 | 930.006 | 512.015 | 208.979 |
| Cash From Operating Activities | 7.574 | 30.302 | 22.958 | 15.364 | 7.617 |
| Amortization | 149.786 | 599.169 | 461.782 | 320.55 | 172.094 |
| Deferred Taxes | -66.061 | -292.251 | -146.874 | -82.315 | -45.339 |
| Non-Cash Items | 81.207 | 875.52 | 421.208 | 208.514 | 49.707 |
| Changes in Working Capital | 78.782 | 283.297 | 154.268 | 13.59 | 23.253 |
| Cash From Investing Activities | -4.822 | -446.23 | -121.852 | -126.454 | -37.292 |
| Capital Expenditures | -4.822 | -498.194 | -113.816 | -118.718 | -37.292 |
| Other Investing Cash Flow Items, Total | 51.964 | -8.036 | -7.736 | 0 | |
| Cash From Financing Activities | -29.788 | -529.491 | -549.087 | -260.034 | -270.811 |
| Financing Cash Flow Items | -43.266 | -45.443 | -42.632 | -40.065 | -33.776 |
| Issuance (Retirement) of Stock, Net | 21.228 | 97.966 | 67.809 | 46.549 | 21.729 |
| Issuance (Retirement) of Debt, Net | -7.75 | -582.014 | -574.264 | -266.518 | -258.764 |
| Foreign Exchange Effects | 0.331 | -6.222 | -11.157 | -5.71 | -1.489 |
| Net Change in Cash | 286.429 | 290.034 | 247.91 | 119.817 | -100.613 |
| Cash Taxes Paid | 94.681 | ||||
| Cash Interest Paid | 270.671 |
| Investor Name | Investor Type | Percent Outstanding | Shares Held | Shares change | Holdings Date | Turnover Rating |
|---|---|---|---|---|---|---|
| The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 10.0037 | 6315834 | 173293 | 2023-06-30 | LOW |
| BlackRock Institutional Trust Company, N.A. | Investment Advisor | 8.7097 | 5498852 | 130439 | 2023-06-30 | LOW |
| State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 3.7577 | 2372395 | 42703 | 2023-06-30 | LOW |
| LSV Asset Management | Investment Advisor | 3.6692 | 2316547 | -1856 | 2023-06-30 | LOW |
| Wellington Management Company, LLP | Investment Advisor/Hedge Fund | 2.9581 | 1867582 | 11642 | 2023-06-30 | LOW |
| JP Morgan Asset Management | Investment Advisor | 2.554 | 1612482 | -297493 | 2023-06-30 | LOW |
| Samlyn Capital, LLC | Hedge Fund | 2.1323 | 1346230 | 557605 | 2023-06-30 | HIGH |
| Polaris Capital Management, LLC | Investment Advisor | 2.0538 | 1296660 | -11200 | 2023-06-30 | LOW |
| Renaissance Technologies LLC | Hedge Fund | 2.0434 | 1290109 | 35500 | 2023-06-30 | HIGH |
| Deep Track Capital LP | Hedge Fund | 1.9799 | 1250000 | 50000 | 2023-06-30 | HIGH |
| Columbia Threadneedle Investments (US) | Investment Advisor/Hedge Fund | 1.9559 | 1234872 | 66367 | 2023-06-30 | LOW |
| Mulligan (Seamus C) | Individual Investor | 1.8529 | 1169814 | 3075 | 2023-08-11 | LOW |
| Franklin Advisers, Inc. | Investment Advisor/Hedge Fund | 1.7308 | 1092730 | -192632 | 2023-06-30 | LOW |
| Swedbank Robur Fonder AB | Investment Advisor/Hedge Fund | 1.7239 | 1088389 | 18395 | 2023-06-30 | LOW |
| Fidelity Management & Research Company LLC | Investment Advisor | 1.6451 | 1038652 | 129999 | 2023-06-30 | LOW |
| Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 1.5809 | 998067 | 44286 | 2023-06-30 | LOW |
| Dimensional Fund Advisors, L.P. | Investment Advisor/Hedge Fund | 1.3019 | 821923 | -18080 | 2023-06-30 | LOW |
| Avidity Partners Management LP | Hedge Fund | 1.1131 | 702778 | 24878 | 2023-06-30 | HIGH |
| Pacer Advisors, Inc. | Investment Advisor | 1.0839 | 684289 | 206243 | 2023-06-30 | HIGH |
| The Baupost Group, L.L.C. | Investment Advisor/Hedge Fund | 1.0671 | 673696 | 195000 | 2023-06-30 | LOW |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Jazz Pharma Company profile
About Jazz Pharmaceuticals PLC
Jazz Pharmaceuticals Public Limited Company is a biopharmaceutical company. The Company is focused on developing and commercializing products that address unmet medical needs. The Company has a diverse portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology. The Company's lead marketed products include Xyrem (sodium oxybate oral solution) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; Erwinaze for the treatment of acute lymphoblastic leukemia (ALL), and Defitelio (defibrotide) for the treatment of severe hepatic veno-occlusive disease (VOD). The Company also commercializes Prialt, an intrathecally administered infusion of ziconotide, approved by the FDA for the management of severe chronic pain in patients for whom intrathecal therapy is warranted, and who are intolerant of or refractory to other treatment, such as systemic analgesics, adjunctive therapies or intrathecal morphine.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Jazz Pharmaceuticals PLC revenues increased 31% to $3.09B. Net loss totaled $329.7M vs. income of $238.6M. Revenues reflect Sunosi segment increase from $28.3M to $2.34B, Zepzelca segment increase from $90.4M to $246.8M, United States segment increase of 32% to $2.82B, Europe segment increase of 31% to $230.2M. Net loss reflects Selling.
Equity composition
Common Stock $.0001 Par, 4/11, 150M auth., 40,741,809 issd. Insiders & stakeholders own 2.30%. IPO 6/1/07, 6M shares @ $18 per share by Morgan Stanley & Co. Incorporated, Lehman Brothers Inc. 5/07 Reverse stock split 1 for 11.06701. PO: 7/08, 3.8M shares.
| Industry: | Pharmaceuticals (NEC) |
Fifth Fl
Waterloo Exchange
DUBLIN
DUBLIN 4
IE
Income Statement
- Annual
- Quarterly
News
EUR/USD tests key support
EUR/USD is currently testing a key support level after the Federal Reserve indicated a potential extension of higher interest rates.
14:32, 21 September 2023
BoE leaves rates unchanged, GBP drops further as investors look for more clarity
The Bank of England has left rates unchanged at 5.25% with a 5-4 vote split after CPI dropped more than expected in August
11:45, 21 September 2023
GBP softer after CPI surprise, JPY focused on any further hints from Ueda
GBP drops after a softer CPI reading scares investors about the BoE intentions. JPY on the lookout for further policy tweaks from Governor Ueda.
12:42, 20 September 2023
How to Trade The Break & Retest
In this week's instalment, we delve into the Break & Retest pattern—a strategic approach to navigating breakout trades. If you've wrestled with the frustration of false breakouts, incorporating this pattern into your trading toolkit may help you overcome this challenge and put you on the path to becoming a more confident and consistent trader.
11:59, 20 September 2023
Cable coils near lows ahead of Fed and BoE rate decisions
It’s a big week for Cable (GBP/USD) as both the Federal Reserve and the Bank of England are set to make crucial rate decisions.
14:16, 19 September 2023
FTSE 100 Technical Outlook - 18 September 2023
In prior technical outlooks, we highlighted the importance of staying alert in sleepy markets, and last Thursday’s developments on the FTSE 100 serve as a prime illustration of this principle.
06:55, 19 September 2023
Market Analysis: FTSE 100 boosted by ECB rate hike end and iron ore rally
The FTSE 100 rose over 2% on Thursday as the ECB announced no more rate hikes for now.
13:46, 15 September 2023People also watch
Still looking for a broker you can trust?
Join the 555.000+ traders worldwide that chose to trade with Capital.com